Q-omics provides the consensus-scored DGCR6L profile across patient tissues and cancer cell-line models. DGCR6L expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, DGCR6L is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, DGCR6L RNA expression shows 18,673 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, HNSC, and THYM as cancer lineages where DGCR6L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DGCR6L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DGCR6L survival associations across molecular data types. DGCR6L RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DGCR6L RNA expression–survival associations across cancer types. High DGCR6L expression shows unfavorable associations in ACC and KICH, but favorable associations in KIRP, LUAD, READ and ESCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for DGCR6L RNA expression.
This table summarizes DGCR6L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for DGCR6L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DGCR6L shows lower tumor expression in KIRP and KICH and higher tumor expression in HNSC, LUSC, BLCA and BRCA. The HNSC box plot shows higher DGCR6L RNA expression in tumor versus normal tissue (log2 FC = +0.681, t-test p < 0.001).
This table shows molecular features associated with DGCR6L in patient tissues and cancer cell lines. In patient samples, DGCR6L shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, DGCR6L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and CNS.
